Keeping Track Of Withdrawals: Libtayo, Parsaclisib Applications Pulled Due To Postmarketing Issues

 
• By Sue Sutter

Changing therapeutic landscape may have complicated regulatory plans for Regeneron/Sanofi’s PD-1 inhibitor in second-line cervical cancer, while accelerated approval confirmatory trial timeline appears to have been an issue for Incyte’s PI3-kinase inhibitor in lymphoma.

Ship reversing course
Like a ship at sea, cancer drug sponsors are reversing course on applications under FDA review. • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers